Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...

Increased Intracranial Pressure ll: Pathophysiology

Increased Intracranial Pressure ll: Pathophysiology

Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Revisiting dose-finding of monoclonal antibodies in migraine.

The journal of headache and pain·2023

Same author

Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial.

Expert review of pharmacoeconomics & outcomes research·2023

Same author

Migraine: from pathophysiology to treatment.

Journal of neurology·2023

Same author

Evaluating migraine with typical aura with neuroimaging.

Frontiers in human neuroscience·2023

Same author

Non-invasive neuromodulation of the cervical vagus nerve in rare primary headaches.

Frontiers in pain research (Lausanne, Switzerland)·2023

Same author

Effectiveness and safety profile of greater occipital nerve blockade in cluster headache: a systematic review.

Journal of neurology, neurosurgery, and psychiatry·2023

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Emerging therapies for migraine.

Peter J Goadsby¹

¹Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. peterg@ion.ucl.ac.uk

Nature Clinical Practice. Neurology

|November 6, 2007

Summary

New migraine treatments are under investigation, offering hope for better management of this disabling brain disorder. Research includes novel preventive and acute therapies, with promising results from neurostimulation and disappointing outcomes from patent foramen ovale closure.

Area of Science:

Neurology
Neuroscience
Pharmacology

Background:

Migraine is a prevalent and disabling neurological disorder with significant clinical and economic impact.
Current migraine treatments are categorized as preventive or acute, but this distinction may evolve.
There is a recognized need for improved and additional management strategies for migraine.

Purpose of the Study:

To review current and emerging therapeutic strategies for migraine management.
To highlight ongoing clinical investigations into novel migraine treatments.
To provide an optimistic outlook on advancements in migraine therapy.

Main Methods:

Review of ongoing clinical trials for migraine prevention and acute treatment.
Inclusion of pharmacological and device-based therapeutic approaches.

More Related Videos

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Related Experiment Videos

Last Updated: Jul 10, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Discussion of investigational agents targeting specific pathways like nitric oxide and CGRP.

Main Results:

Several preventive therapies are in clinical trials, including tonabersat, inducible nitric oxide synthase (NOS) inhibitors, and botulinum toxin A.
Neurostimulation of the occipital nerve shows promising results for migraine prevention.
Initial studies on patent foramen ovale closure for migraine prevention yielded disappointing results.
Investigational acute treatments include calcitonin gene-related peptide receptor antagonists, vanilloid TRPV1 receptor antagonists, and NOS inhibitors.

Conclusions:

The field of migraine treatment is advancing with numerous promising therapeutic options in development.
Patients can anticipate significant benefits from ongoing research and emerging management strategies.
Continued investigation into novel pharmacological and device-based interventions is crucial for improving migraine care.